Paradigm Biopharmaceuticals Limited Overview
Paradigm Biopharmaceuticals is a Melbourne-based, pre-revenue drug-repurposing company that spent more than a decade developing a single molecule — pentosan polysulfate sodium (PPS), an old semi-synthetic polysaccharide derived from beech-wood xylan — as a subcutaneous injection (iPPS, branded Zilosul®) for knee osteoarthritis pain and function. The thesis was that a six-week course of injections could deliver a durable, non-opioid benefit positioned between conservative care and knee replacement, with possible structural (cartilage and bone-marrow-lesion) effects as differentiation. The company held US FDA Fast Track designation, ran a TGA Special Access Scheme generating token revenue, and in 2025 added an oral PPS-plus-COX-2 combination (Pentacoxib®) through the acquisition of Proteobioactives. Its fate was binary on the pivotal PARA_OA_012 trial. The September 2026 futility outcome, combined with secured convertible note obligations and thin net assets, pushed the company into voluntary administration, where its residual value now lies in IP, clinical data and any recapitalisation.
Company's own description (paraphrased from FY2026 Annual Report). Paradigm describes itself as a late-stage clinical development company whose purpose is to improve patients' health and quality of life by developing and delivering pharmaceutical therapies, with a vision of becoming a recognised global leader in developing and commercialising innovative therapies. Its stated principal activity is researching and developing therapeutic products for human use. Its standard boilerplate describes the current focus as developing iPPS for diseases in which inflammation plays a major pathogenic role, drawing on the anti-inflammatory and tissue-regenerative properties attributed to PPS, with osteoarthritis at Phase 3.
Independent characterisation. Paradigm was, in substance, a single-asset, single-indication repurposing biotech. PPS has a long history as an approved oral product (in some markets for interstitial cystitis) and as a veterinary injectable; Paradigm's proprietary angle was the subcutaneous human formulation, dose regimen (2 mg/kg twice weekly for six weeks), method-of-use patents, and a clinical dataset in knee OA. Third-party commentary notes that Germany's Bene Pharmachem was the sole manufacturer of the active ingredient, creating supply concentration (Stockhead, 2023).
Business model. Development-stage licensing/commercialisation model. Management's stated plan was to generate Phase 3 evidence, file an NDA with the FDA, and pursue regional and global licensing (discussions at BIO International Convention 2026). No commercial product approval was ever obtained.
Revenue model mix (FY2026).
Roughly 99% of reported income is non-operating (R&D Tax Incentive and interest). Product, service, subscription and licensing revenue: none, other than SAS access fees.
Value chain position. Clinical development sponsor. Manufacturing of API outsourced (Bene Pharmachem per press commentary); clinical operations outsourced to Advanced Clinical (global CRO) and Nordic Bioscience Clinical Development A/S (complementary CRO for imaging, biomarkers, Hong Kong and Moldova expansion).
Customer types and end-markets. Prospective: physicians (rheumatology, orthopaedics, sports medicine, primary care) treating symptomatic knee OA; payers; pharma licensing partners. Current: a small number of experienced Australian prescribers under SAS (including chronic arthralgia from Ross River virus infection). Pentacoxib® was initially targeted at veterinary applications.
Strategy
Stated strategy (FY2026 Annual Report, paraphrased). The FY2026 report framed strategy around five themes: (1) shifting from trial execution to clinical evidence generation after full recruitment; (2) funding certainty through key Phase 3 milestones via staged financing; (3) building an evidence package beyond registration (Day 112 pain, Day 168 durability and qMRI, Day 404 long-term durability); (4) positioning Zilosul® as a differentiated non-opioid therapy between conservative care and knee replacement, aligned with the FDA's May 2026 draft guidance on non-opioid analgesics; and (5) widening the PPS platform through Pentacoxib® and translational research. Management also said planning for a potential confirmatory trial had commenced and NDA, manufacturing readiness and partnering work would continue.
Initiatives in the last 24 months.
ESG commitments: none disclosed. Medium-term financial targets: none; prior guidance pointed to an Interim Analysis (September 2026) and top-line Phase 3 results (Q1 CY2027), both now superseded. The company said on 30 September 2026 that the clinical review and restructuring would take at least eight weeks.
Product Portfolio
| Asset | Description | Key specifications | Target patient/customer | Stage / latest status (Oct 2026) | Pricing |
|---|---|---|---|---|---|
Zilosul® (iPPS) — knee OA | Subcutaneous injectable pentosan polysulfate sodium | 2 mg/kg twice weekly for six weeks; primary endpoint weekly average daily pain (11-point NRS) at Day 112; WOMAC function secondary; quantitative MRI at Day 168 and Day 404 | Adults with symptomatic knee OA with persistent pain despite conservative care | Phase 3 PARA_OA_012 interim analysis met futility (23 Sep 2026); FDA Fast Track designation retained; future path under administrators' review | Not commercialised |
iPPS via TGA Special Access Scheme | Pay-for-use access for eligible patients | Restricted to experienced prescribers; includes Ross River virus chronic arthralgia and re-treatment | Australian physicians | Ongoing in FY2026 (A$80,150 revenue); status in administration not disclosed | Pay-for-use; price not disclosed |
Pentacoxib® | Oral fixed combination of PPS with a selective COX-2 inhibitor | Acquired via Proteobioactives (founded by PPS pioneer Prof. Peter Ghosh); exclusive global rights | Initially veterinary; potential earlier-stage human OA | Early formulation development | Not commercialised |
iPPS — mucopolysaccharidosis (MPS) | iPPS in a rare lysosomal storage disease | Previously described as Phase 2 | Rare-disease patients | Not featured in FY2026 reporting; status not publicly disclosed | — |
Respiratory program (Rhinosul® trademark) | PPS in respiratory/inflammatory indications | Trademark registered | — | Described in FY2025 AR as strategic for future; no active trial disclosed | — |
Translational research (City St George's, University of London) | qMRI plus gene/protein profiling of tissue from knee replacement | Bone marrow lesions, cartilage, synovium | Scientific differentiation | Established FY2026 | — |
Financial Narrative
Income statement (A$ M; fiscal years ending 30 June).
Sources: FY2026 Annual Report (five-year income, loss, EPS; FY2026 and FY2025 line items); StockAnalysis/TipRanks (FY2022–FY2025 R&D, SG&A, operating income, EBITDA, SAS revenue). FY2026 operating income is derived from the FY2026 income statement (SAS revenue less cost of sales, R&D, G&A and commercial expense). FY2026 EBITDA is not disclosed and is left blank. Income tax is nil in all years (losses; R&D incentive booked as other income). Gross, operating, EBITDA and net margins are not meaningful (product revenue below A$0.1m; vendor-computed operating margins run to tens of thousands of percent negative). Total-income CAGR FY2022–FY2026: approximately -1.9% (derived).
Balance sheet (A$ M, 30 June).
Sources: FY2026 Annual Report (FY2025–FY2026; FY2024 restated opening equity); StockAnalysis (FY2022–FY2024 assets, cash, net cash). Blank cells: not in sources reviewed. Goodwill: nil. Total debt split: all FY2026 borrowings (convertible notes) classified current; no long-term debt other than A$0.36m non-current lease liability. Notable FY2026 movements: trade payables jumped from A$2.73m to A$17.15m, reflecting accrued Phase 3 costs — central to the later solvency crisis. Net tangible assets per share fell from 5.33 cents to 0.44 cents.
Cash flow (A$ M).
Sources: FY2026 Annual Report; TipRanks/StockAnalysis for FY2022–FY2024. FY2026 FCF derived as OCF plus investing outflows (including A$0.49m intangible/IP payment). Capex is negligible in all years. FY2026 also included A$2.25m of note redemptions and A$16.18m of notes converted into shares (non-cash).
Ratios.
All ratios derived from annual report figures; InvestSMART reports FY2026 ROE of -1,623% on closing equity (methodology difference). ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful for a pre-revenue, net-cash, loss-making biotech.
Commentary. The five-year record is a pure burn profile. Spending peaked in FY2023–FY2024 (R&D A$52.7m and A$58.3m) with the PARA_OA_002 program, collapsed in FY2025 (A$17.7m) during the regulatory reset and protocol re-design for a single pivotal trial, then tripled again in FY2026 (A$53.9m) as PARA_OA_012 enrolled 538 patients across 57 sites. Importantly, the company ran each pivotal phase with less than one year of cash in hand: at 30 June 2026 it held A$15.4m of cash against current liabilities of A$26.6m, including A$17.2m of payables and A$7.0m of secured notes. The going-concern basis in the FY2026 accounts relied on R&D refunds (A$13.0m receivable), the undrawn US$7m of Obsidian capacity (subject to minimum-cash and other conditions) and potential capital raisings — all of which became uncertain or unavailable once the interim analysis failed. The FY2026 finance cost of A$2.46m (from A$0.01m) shows the price of the note facility. The equity base was eroded to A$3.47m, explaining why administration followed within a week of the futility announcement.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products/programs |
|---|---|---|
Single segment: PPS therapeutics R&D | All operations | Zilosul® (iPPS, knee OA); SAS supply; Pentacoxib® (oral PPS + COX-2); historical MPS and respiratory (Rhinosul trademark) programs |
Results by Segment and Revenue by Segment (%)
| Metric (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
SAS product revenue | 0.07 | 0.05 | 0.08 |
Total income incl. R&D Tax Incentive | 6.44 | 7.11 | 8.13 |
Pre-tax loss | -58.73 | -18.77 | -56.33 |
Share of total income (%) | 100 | 100 | 100 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
SAS product revenue (AUD Mn) | 0.08 | 0.05 | 0.07 | 0.05 | 0.08 |
Total income incl. R&D Tax Incentive (AUD Mn) | 8.79 | 8.58 | 6.44 | 7.11 | 8.13 |
Gross profit on SAS (AUD Mn) | -0.06 | -0.02 | -0.01 | -0.02 | 0.07 |
R&D expense (AUD Mn) | 39.01 | 52.68 | 58.33 | 17.74 | 53.92 |
G&A plus commercial expense (AUD Mn) | 8.85 | 7.39 | 6.77 | 5.58 | 7.26 |
Operating income, excl. other income (AUD Mn) | -47.93 | -60.09 | -65.11 | -23.34 | -61.12 |
EBITDA (AUD Mn) | -46.82 | -59.06 | -64.54 | -25.25 | — |
Finance costs (AUD Mn) | 0.03 | 0.02 | 0.01 | 0.01 | 2.46 |
Pre-tax income (AUD Mn) | -39.25 | -51.91 | -58.73 | -18.77 | -56.33 |
Net income (AUD Mn) | -39.25 | -51.91 | -58.73 | -18.77 | -56.33 |
Basic EPS (A$ cents) | -16.87 | -20.78 | -20.03 | -5.97 | -17.91 |
Diluted EPS (A$ cents) | -16.87 | -20.78 | -20.03 | -5.97 | -17.91 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 39.67 | 56.33 | 17.82 | 16.82 | 15.37 |
Trade and other receivables (AUD Mn) | 6.72 | 6.81 | 6.07 | 6.37 | 13.06 |
Total current assets (AUD Mn) | 47.17 | 63.79 | 25.24 | 24.13 | 29.15 |
Intangible assets (AUD Mn) | 2.95 | 2.95 | 2.95 | 0.41 | 0.91 |
Total assets (AUD Mn) | 50.69 | 67.07 | 28.37 | 24.57 | 30.55 |
Convertible notes liability (AUD Mn) | 0 | 0 | 0 | 0 | 7.00 |
Derivative liability (AUD Mn) | 0 | 0 | 0 | 0 | 1.65 |
Lease liabilities (AUD Mn) | — | — | — | 0.01 | 0.51 |
Total liabilities (AUD Mn) | — | — | — | 3.39 | 27.08 |
Total equity (AUD Mn) | — | — | 24.79 | 21.18 | 3.47 |
Net cash, cash less notes and leases (AUD Mn) | 39.10 | 56.04 | 17.63 | 16.81 | 7.86 |
Working capital (AUD Mn) | — | — | — | 20.89 | 2.57 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -32.21 | -45.19 | -65.94 | -15.99 | -43.69 |
Investing cash flow (AUD Mn) | 0 | 0 | 0 | 0.05 | -0.55 |
Free cash flow (AUD Mn) | -32.21 | -45.19 | -65.94 | -15.99 | -44.18 |
Financing cash flow (AUD Mn) | 0.07 | 62.53 | 28.18 | 14.99 | 43.69 |
Equity issue proceeds (AUD Mn) | — | — | — | 16.00 | 21.57 |
Convertible note proceeds (AUD Mn) | 0 | 0 | 0 | 0 | 25.42 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROA on average assets (%) | -57.9 | -88.2 | -123.1 | -70.9 | -204.4 |
ROE on average equity (%) | — | — | — | -81.6 | -456.9 |
Current ratio (x) | — | — | — | 7.46 | 1.10 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 2.16 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia — SAS product revenue (AUD Mn) | 0.07 | 0.05 | 0.08 |
Australia — R&D Tax Incentive and other income (AUD Mn) | 6.38 | 7.05 | 8.05 |
United States revenue (AUD Mn) | 0 | 0 | 0 |
Rest of world revenue (AUD Mn) | 0 | 0 | 0 |
Country Overview
| Country | Clinical sites |
|---|---|
United States | 41 |
Australia | 12 |
Moldova | 3 |
Hong Kong | 1 |
Share Price and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.97 | 0.99 | 0.26 | 0.30 | 0.17 |
Dividends declared (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Basic EPS (A$ cents) | -16.87 | -20.78 | -20.03 | -5.97 | -17.91 |
Analyst Conclusions
Management guidance. Pre-futility guidance (interim September 2026; top-line Q1 CY2027; NDA preparation; confirmatory trial planning) is withdrawn in substance. The only current guidance is that the clinical review and restructuring will take at least eight weeks and that the goal is a DOCA preserving IP and clinical data.
Consensus expectations. No valid post-event consensus exists.
Bull case (low probability)
-
Missing-data imputation drove the futility outcome; a per-protocol or completer analysis might show a treatment effect worth a smaller, better-run confirmatory study, keeping Fast Track relevance.
-
A DOCA with Obsidian or a new sponsor could recapitalise a clean shell with the IP, data and Pentacoxib® intact at low cost.
-
Pentacoxib® in veterinary markets offers a nearer, cheaper path to revenue than human OA.
Bear case (base expectation)
-
A pre-specified futility boundary is a strong negative signal; regulators judge the ITT analysis, not post-hoc subsets.
-
Secured creditor priority and A$17m+ of payables mean existing shareholders likely face severe dilution or wipe-out under any DOCA.
-
Repeated failure to secure regulatory shortcuts (FDA 2018, TGA 2025) and now Phase 3 futility will deter partners.
Catalysts and monitorables (next 12 months)
-
Outcome of 9 October 2026 creditors' meeting and committee of inspection formation.
-
Administrators' report to creditors and second meeting (DOCA vs liquidation vote).
-
Unblinded Phase 3 data review disclosures, including the size and cause of missing data.
-
Treatment of Obsidian's secured notes and any new funding proposal.
-
ASX reinstatement or delisting decision.
-
PAROB option expiry on 1 December 2026 (worthless absent reinstatement and recovery).
-
Status of the remaining R&D Tax Incentive receivable (~A$8m after the July refund) and trial wind-down costs.
Analyst verdict. Paradigm Biopharmaceuticals is a case study in the asymmetric risks of a single-asset, cash-constrained biotech. For a decade the company kept the PPS-in-osteoarthritis thesis alive through Phase 2 data, an FDA Fast Track designation, expanded-access programs and serial equity raisings, while never building more than about a year of runway. By FY2026 it had executed operationally — 538 participants, 57 sites, clean DSMB safety reviews — but did so on a balance sheet with A$3.5m of net assets, A$17m of payables and secured convertible notes whose conversion and covenant mechanics favoured the lender. The September 2026 interim analysis was therefore not merely a clinical readout but a solvency test. When the DSMB declared futility, citing a significant amount of missing data, the financing structure unravelled within a week: the last drawdown was reversed and administrators were appointed. From an equity standpoint, the investment case as previously constructed no longer exists. The relevant questions now concern recovery value: whether the IP, the Phase 3 dataset, the Fast Track status and Pentacoxib® can be packaged into a DOCA attractive enough for Obsidian or a new sponsor to fund, and what, if anything, survives for ordinary shareholders after secured and unsecured creditors. The company's claim that missing-data imputation drove the result is plausible in principle and worth understanding, but such explanations rarely rescue a futile pivotal trial in regulators' eyes without a fresh, adequately powered study — something a company in administration cannot fund. Our assessment is that the probability of meaningful equity recovery is low; any residual value is more likely to accrue to creditors and a recapitalising party. Investors and counterparties should monitor the administrators' report, the DOCA terms and the detailed data review, and treat all pre-September 2026 valuations, targets and guidance as void.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education |
|---|---|---|---|---|
Paul Rennie | Founder; Managing Director and Executive Chairman | MD since 22 Nov 2022 (previously non-executive chair) | Boehringer Mannheim (now Roche Diagnostics); Merck national sales and marketing manager; Director of business development at Soltec (FH Faulding); led commercialisation of Recaldent®; inaugural COO and later EVP New Product Development at Mesoblast; director of NeuroScientific Biopharmaceuticals 2021–2023 | BSc, MBM, Grad Dip Commercial Law, MSTC |
Amos Meltzer | Non-Executive Director | 9 Dec 2020 | Scientist and IP lawyer; former General Counsel at Compugen and Gilat; former CEO of Immuron; Chief Legal Officer of Synchron; chair of Maverick LifeSciences | — |
Matthew Fry | Non-Executive Director | 4 Mar 2024 | Founder, CEO and MD of AM Diagnostics; US expansion 2009; TGA/FDA regulatory experience | — |
Dr Donna Skerrett | Chief Medical Officer (former Executive Director, 3 Jul 2020 – 20 Nov 2024) | — | Led PARA_OA_012 execution; signalled in Aug 2026 that a new CMO would be recruited | — |
Abby Macnish Niven | Company Secretary (and CFO function per AR heading) | 30 Aug 2022 | 20+ years in wealth management | BComm, BSc, CFA, GAICD |
Simon White | Director of Investor Relations | — | Long-standing IR contact | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Salary and fees | Annual leave | Cash bonus | Super | Share-based payments | Total |
|---|---|---|---|---|---|---|
Paul Rennie | 1,010,252 | 55,868 | 138,596 | 29,932 | -947,684 | 286,964 |
Amos Meltzer | 82,800 | 0 | 0 | 9,936 | 0 | 92,736 |
Matthew Fry | 80,000 | 0 | 0 | 0 | 0 | 80,000 |
Major Shareholders
| Holder | Shares | Approx. % of 584.8m | Source/date |
|---|---|---|---|
Paul Rennie (director) | 20,809,425 | 3.6 | FY2026 AR (Aug 2026) |
Matthew Fry (director) | 1,596,300 | 0.3 | FY2026 AR |
Allianz Asset Management GmbH | 17,372,860 | 3.0 | Simply Wall St (dated, pre-2026 dilution) |
Collins St Asset Management | 15,148,692 | 2.6 | Simply Wall St (dated) |
RBC Global Asset Management | 11,509,378 | 2.0 | Simply Wall St (dated) |
Kzee Pty Ltd | 11,380,902 | 1.9 | Simply Wall St (dated) |
Competitive Landscape
Key Competitors
| Competitor / product class | Modality | Relative position vs Paradigm |
|---|---|---|
Oral and topical NSAIDs (multiple generics) | Standard of care | Entrenched, cheap; GI/CV safety limits — Paradigm's core positioning argument |
Pacira BioSciences — Zilretta (extended-release triamcinolone) | Intra-articular steroid | Approved US product in knee OA pain |
Sanofi — Synvisc family; Bioventus — Durolane; Anika Therapeutics — HA products; Ferring — Euflexxa | Hyaluronic acid injections | Established procedure-based market with variable evidence |
Grünenthal — resiniferatoxin (RTX) | Intra-articular TRPV1 agonist | Late-stage OA knee pain program |
Kolon TissueGene — TG-C | Cell/gene therapy | Late-stage disease-modification candidate |
Biosplice — lorecivivint | Wnt pathway modulator | Late-stage OA program |
Vertex — suzetrigine (Journavx) | NaV1.8 non-opioid analgesic | Approved for acute pain; competitor for "non-opioid" narrative |
Cynata Therapeutics (ASX: CYP) — CYP-004 | MSC therapy | ASX peer in OA |
Mesoblast (ASX: MSB) | Cell therapy | ASX peer, pain/back programs |
Generic PPS (Elmiron-type oral products, veterinary PPS) | Same molecule | Risk of off-label/compounded competition where patents absent |



